Company* (Country; Symbol) | Company |
Type/Product Area | Terms/Details (Date) |
Epoch Biosciences Inc. (EBIO) |
Associated Regional and University Pathologists Inc. |
Epoch will supply the national reference laboratory its MGB Eclipse Detection Reagents |
They will collaborate on development and validation of infectious disease assays for use in the laboratory (5/4) |
Harvard Bioscience Inc. (HBIO) |
The Automation Partnership* (UK) |
Deal to incorporate Harvard's microscopy reader technology into TAP's Cello cell culture system |
The deal involves technology from Harvard subsidiary MAIA Scientific; terms were not disclosed (5/3) |
Orchid BioSciences Inc. (ORCH) |
Cybergenetics Corp.* |
The Orchid Cellmark unit licensed Cybergenetics' TrueAllele software for forensics applications |
Terms of the deal were not disclosed; it is the first licensing of the technology by a private U.S. laboratory (5/3) |
Paradigm Genetics Inc. (PDGM) |
Experimental Pathology Laboratories Inc. |
Collaboration to further develop Paradigm's automated pathology software |
The software will be installed at EPL, which also will serve as the contact for Paradigm's clients on veterinary pathology topics; a broader deal is being discussed (6/22) |
Tarpan Therapeutics Inc.* |
IGI Inc. (AMEX:IG) delivery technology |
Tarpan got a sublicense for use of PTH 1-34 to treat skin disorders using IGI's Novasome |
IGI gets an up-front payment and potential milestones and royalties; Tarpan assumes all clinical trial costs (5/4) |
Notes: | |||
* Private companies are indicated with an asterisk. | |||
Unless otherwise noted, the trading symbols listed for public companies are on the Nasdaq market. | |||
